8-K: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split to Maintain Nasdaq Listing

TransCode Therapeutics' stockholders approved a 1-for-28 reverse stock split aimed at increasing the company's stock price to meet Nasdaq's minimum bid requirement.

Summary

• TransCode Therapeutics held a Special Meeting of Stockholders on May 2, 2025, where two proposals were approved.
• The first proposal was to authorize a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-40.
• The Board of Directors determined the reverse stock split ratio to be 1-for-28.
• The reverse stock split is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
• The second proposal approved was to adjourn the meeting if there were insufficient votes for the reverse stock split proposal, but this was not needed.
• The reverse stock split will reduce the number of outstanding shares from 23,341,336 to approximately 833,620.
• Proportional adjustments will be made to the exercise prices of outstanding stock options and warrants, as well as to the number of shares issued and issuable under the company's stock incentive plans.
• The effective date of the reverse stock split will be announced at least two business days prior to its implementation.

Sentiment

Score: 5

Explanation: The announcement is neutral, detailing a procedural action to maintain Nasdaq listing. While reverse stock splits can be viewed negatively, the company is taking steps to remain compliant.

Positives

• The reverse stock split aims to ensure continued listing on the Nasdaq Capital Market, which can maintain investor confidence.
• Stockholders of record are not required to take any action to receive post-split shares in book-entry.

Negatives

• Reverse stock splits are often viewed negatively by investors as they can indicate financial distress or an attempt to artificially inflate the stock price.
• The reverse stock split will reduce the number of outstanding shares from 23,341,336 to approximately 833,620.

Risks

• The company's future performance and ability to maintain Nasdaq listing are subject to risks and uncertainties.
• The announcement contains forward-looking statements that are subject to risks and uncertainties, including the company's expectations regarding the effect of the reverse stock split and its continued listing on Nasdaq.

Future Outlook

The company expects the reverse stock split to increase its per share trading price and enable it to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market; the effective date of the split will be announced at least two business days prior to implementation.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices; this action reflects TransCode's efforts to remain compliant with Nasdaq requirements.

Comparison to Industry Standards

• Many biotech companies facing similar challenges, such as low stock prices and Nasdaq listing requirements, have implemented reverse stock splits.
• For example, companies like Geron Corporation and Ocugen, Inc. have previously used reverse stock splits to regain compliance with minimum bid price rules.
• The success of a reverse stock split in maintaining listing and improving investor sentiment varies, and often depends on the company's underlying financial health and future prospects.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they hold, but the proportional value should remain the same immediately following the split.
• The reverse stock split aims to maintain the company's listing on Nasdaq, which could benefit shareholders by maintaining liquidity and access to capital markets.

Next Steps

• The company will announce the effective date of the reverse stock split at least two business days prior to its implementation.
• Vstock Transfer LLC will act as the exchange agent for the reverse stock split.

Key Dates

Keywords

reverse stock split, Nasdaq, RNAZ, TransCode Therapeutics, stockholders, common stock, listing compliance